DOT1L and head and neck squamous cell carcinoma: From Fig. 12A–I, we found that HNSCC patients in cluster 3 were sensitive to most drugs, including AMG-319 (PI3K inhibitor), AZD1208 (PIM inhibitor), AZD4547 (FGFR inhibitor), EPZ004777 (DOT1L inhibitor), Nilotinib (Bcr-abl inhibitor), and OSI-027 (mTOR inhibitor).